GlassScriptPhysician profile
Allison L Agwu
NPI 1598802027
$58,100.12
in general payments reported to CMS, 2019-2025
6 companies · $7,194 in 2025
The $7,194 reported for 2025 was more than what 98% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27K · 2020: $469 · 2021: $7,845 · 2022: $1,220 · 2023: $7,824 · 2024: $6,636 · 2025: $7,194.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $21K · Travel and Lodging: $710 · Food and Beverage: $435.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $20,508.97 |
| Travel and Lodging | $709.91 |
| Food and Beverage | $435.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $24,829.84 | 2021-2025 | |
| Gilead Sciences, INC. | $19,441.44 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $9,562.80 | 2019-2021 | |
| Theratechnologies INC. | $4,266.04 | 2019 |
2 companies reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Agwu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.